153 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
3 Jun 24
Current report (foreign)
4:05pm
-free survival (PFS) and overall survival (OS) rates were 94% each.
Safety signals were consistent with the known safety profile of CARVYKTI®.1 All … %), and longer mDOR (NR [16-NE]; 16 [8-NE]).
The safety profile in this subgroup analysis was consistent with the known safety profile of cilta-cel.2
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 May 24
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
5:00pm
: June 3, 2024, 4:12 – 4:24 p.m. CDT
Location: Hall D1
Abstract #7505 Oral Presentation
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide … SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED and RECURRENT CYTOPENIA, and SECONDARY HEMATOLOGICAL
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data
6-K
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data … in relapsed and refractory multiple myeloma (“RRMM”) patients with a manageable safety profile.
On February 28, 2022, cilta-cel was approved by the U.S
6-K
EX-99.1
LEGN
Legend Biotech Corp
22 Apr 24
Current report (foreign)
1:06pm
to lenalidomide.
###
CARVYKTI® IMPORTANT SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED and RECURRENT … .
Use of Live Vaccines: The safety of immunization with live viral vaccines during or following CARVYKTI® treatment has not been studied. Vaccination
6-K
85q1k57d
16 Apr 24
Current report (foreign)
7:29am
6-K
EX-99.1
6fs ax6x2
8 Apr 24
Current report (foreign)
7:03am
F-3ASR
n7bpzc
19 Mar 24
Automatic shelf registration (foreign)
7:57am
6-K
EX-99.1
le5he0hs p9iu
15 Mar 24
FDA ODAC votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI based on results from the Phase 3 CARITUDE-4 study
3:18pm
6-K
EX-99.1
2s0 vb7s4fl
11 Mar 24
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
7:52am
6-K
EX-99.1
f3vygul32nu32
23 Feb 24
Current report (foreign)
7:16am
6-K
p9fwyu6wd3 bw
23 Jan 24
Legend Biotech Corporation 6-K
9:00am
6-K
yi5km4
23 Jan 24
Legend Biotech Corporation 6-K
7:30am
6-K
EX-99.1
vf99ltqvcyep
9 Jan 24
Legend Biotech Corporation 6-K
4:01pm
6-K
4urusxz3sv
21 Dec 23
Legend Biotech Corporation 6-K
5:17pm
6-K
EX-99.1
jb714r6r hz28k81q11
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
6-K
cced9jwom
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am